-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Mutation-and MRD-informed Treatment Decisions for the Transplant-Eligible AML Patient

Program: Education Program
Session: AML M&Ms: How to Integrate Mutations and MRD Data
Hematology Disease Topics & Pathways:
Acute Myeloid Malignancies, AML, Combination therapy, Diseases, Therapy sequence, Treatment Considerations, Myeloid Malignancies, Technology and Procedures, Measurable Residual Disease , Molecular testing
Saturday, December 7, 2024, 9:30 AM-10:45 AM

Michael Heuser, MD

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

Disclosures: Heuser: Miltenyi: Consultancy; Qiagen: Honoraria; LabDelbert: Consultancy; Sobi: Honoraria; Pfizer: Consultancy, Honoraria; Bristol-Myers-Squibb: Honoraria; PinotBio: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Loxo Oncology: Research Funding; Karyopharm: Research Funding; Jazz Pharmaceuticals: Honoraria, Research Funding; Glycostem: Consultancy, Research Funding; BergenBio: Research Funding; Astellas: Consultancy, Research Funding; Servier: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria; AvenCell: Consultancy.

See more of: AML M&Ms: How to Integrate Mutations and MRD Data
See more of: Education Program
<< Previous Presentation | Next Presentation >>